Search Results

You are looking at 31 - 40 of 71 items for :

  • "chemotherapy administration" x
  • All content x
Clear All
Full access

Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow

compared specific data points collected regarding chemotherapy administration. These data points were defined in the NCDB as, “Multiagent chemotherapy administered as first course therapy,” which was compared with, “Chemotherapy was not administered. It was

Full access

Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg, and Rudolph M. Navari

Several studies have evaluated the economic impact of CINV on healthcare costs in the United States. Projected additional costs per patient for poorly controlled CINV range from >$7,631 to $10,699 during the first 5 days after chemotherapy administration

Full access

Katy Winckworth-Prejsnar, Elizabeth A. Nardi, James McCanney, F. Marc Stewart, Terry Langbaum, Bruce J. Gould, C. Lyn Fitzgerald, and Robert W. Carlson

. Available at: . Accessed September 10, 2017 . 6. Gilmore TR Schulmeister L Jacobson JO . Quality Oncology Practice Initiative Certification Program: measuring implementation of chemotherapy administration

Full access

Ashley T. Freeman, May Kuo, Lei Zhou, Justin G. Trogdon, Chris D. Baggett, Sascha A. Tuchman, Thomas C. Shea, and William A. Wood

received. Furthermore, generic rather than specific codes are sometimes used. For example, we may identify a code for “intravenous chemotherapy administration,” making it impossible to know exactly what therapy was used for a portion of the population

Full access

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, and Lenora A. Pluchino

, occurring in 30% to 90% of patients with cancer. 54 In select patients undergoing treatment with myelosuppressive chemotherapy, administration of ESAs such as epoetin alfa, with or without iron supplementation, may improve anemia. In May 2018, the FDA

Full access

Keli Turner, Sheelu Varghese, and H. Richard Alexander

Immunosuppression and electrolyte abnormalities are complications related specifically to intraperitoneal chemotherapy administration, but are uncommon. 41 Mortality rates after CRS and HIPEC are between 0% and 7%. 13 , 27 , 36 , 40 , 42 Survival data for

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

frequent endorectal ultrasound staging was uT3N1. Patient characteristics are summarized in Table 1 . Induction Chemotherapy Administration and Toxicities Of the 61 patients who received some or all of their planned chemotherapy, 28 received a full

Full access

Julie Hallet, Laura Davis, Alyson Mahar, Michail Mavros, Kaitlyn Beyfuss, Ying Liu, Calvin H.L. Law, Craig Earle, and Natalie Coburn

), defined using OHIP claims as ≥1 encounters with a medical oncologist. Any physician who submitted billing claims for chemotherapy administration codes (G281, G339, G345, G359, G381) during the study period was classified as a medical oncologist. 23

Full access

Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher

. However, the NCDB is the largest US cancer registry, capturing 70% of incident cancers, and it also includes comprehensive treatment information, including details regarding chemotherapy administration, and is therefore one of the most robust databases for

Full access

Andrew G. Robinson, Xuejiao Wei, William J. Mackillop, Yingwei Peng, and Christopher M. Booth

chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population . J Thorac Oncol 2010 ; 5 : 1529 – 1535 . 27. Baunemann Ott CL Ratna N Prayag R . Survival and treatment patterns in elderly patients with